S&P 500   4,543.97 (-0.13%)
DOW   35,669.61 (+0.19%)
QQQ   373.87 (-0.90%)
AAPL   148.91 (-0.38%)
MSFT   309.03 (-0.56%)
FB   322.71 (-5.61%)
GOOGL   2,751.00 (-3.06%)
TSLA   905.78 (+1.32%)
AMZN   3,341.38 (-2.73%)
NVDA   227.54 (+0.27%)
BABA   176.95 (-0.26%)
NIO   38.64 (-3.33%)
CGC   13.29 (-5.34%)
GE   104.13 (+0.95%)
AMD   119.91 (+0.49%)
MU   67.67 (-1.41%)
T   25.49 (-1.05%)
F   16.29 (-1.57%)
ACB   7.06 (-4.21%)
DIS   169.28 (-1.20%)
PFE   43.08 (+0.51%)
BA   212.90 (-0.67%)
AMC   36.35 (-7.36%)
S&P 500   4,543.97 (-0.13%)
DOW   35,669.61 (+0.19%)
QQQ   373.87 (-0.90%)
AAPL   148.91 (-0.38%)
MSFT   309.03 (-0.56%)
FB   322.71 (-5.61%)
GOOGL   2,751.00 (-3.06%)
TSLA   905.78 (+1.32%)
AMZN   3,341.38 (-2.73%)
NVDA   227.54 (+0.27%)
BABA   176.95 (-0.26%)
NIO   38.64 (-3.33%)
CGC   13.29 (-5.34%)
GE   104.13 (+0.95%)
AMD   119.91 (+0.49%)
MU   67.67 (-1.41%)
T   25.49 (-1.05%)
F   16.29 (-1.57%)
ACB   7.06 (-4.21%)
DIS   169.28 (-1.20%)
PFE   43.08 (+0.51%)
BA   212.90 (-0.67%)
AMC   36.35 (-7.36%)
S&P 500   4,543.97 (-0.13%)
DOW   35,669.61 (+0.19%)
QQQ   373.87 (-0.90%)
AAPL   148.91 (-0.38%)
MSFT   309.03 (-0.56%)
FB   322.71 (-5.61%)
GOOGL   2,751.00 (-3.06%)
TSLA   905.78 (+1.32%)
AMZN   3,341.38 (-2.73%)
NVDA   227.54 (+0.27%)
BABA   176.95 (-0.26%)
NIO   38.64 (-3.33%)
CGC   13.29 (-5.34%)
GE   104.13 (+0.95%)
AMD   119.91 (+0.49%)
MU   67.67 (-1.41%)
T   25.49 (-1.05%)
F   16.29 (-1.57%)
ACB   7.06 (-4.21%)
DIS   169.28 (-1.20%)
PFE   43.08 (+0.51%)
BA   212.90 (-0.67%)
AMC   36.35 (-7.36%)
S&P 500   4,543.97 (-0.13%)
DOW   35,669.61 (+0.19%)
QQQ   373.87 (-0.90%)
AAPL   148.91 (-0.38%)
MSFT   309.03 (-0.56%)
FB   322.71 (-5.61%)
GOOGL   2,751.00 (-3.06%)
TSLA   905.78 (+1.32%)
AMZN   3,341.38 (-2.73%)
NVDA   227.54 (+0.27%)
BABA   176.95 (-0.26%)
NIO   38.64 (-3.33%)
CGC   13.29 (-5.34%)
GE   104.13 (+0.95%)
AMD   119.91 (+0.49%)
MU   67.67 (-1.41%)
T   25.49 (-1.05%)
F   16.29 (-1.57%)
ACB   7.06 (-4.21%)
DIS   169.28 (-1.20%)
PFE   43.08 (+0.51%)
BA   212.90 (-0.67%)
AMC   36.35 (-7.36%)
OTCMKTS:ENDV

Endonovo Therapeutics Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 10/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.02
▼
$0.03
50-Day Range
$0.02
▼
$0.04
52-Week Range
$0.01
▼
$0.10
Volume364,606 shs
Average Volume450,612 shs
Market Capitalization$1.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ENDV News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Endonovo Therapeutics logo

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Headlines

Endonovo Therapeutics Issues Shareholder Update
October 12, 2021 |  finance.yahoo.com
Stanford University Orthopedic Study Collaboration with Endonovo Therapeutics SofPulse® Devices Moves Forward
May 11, 2021 |  finance.yahoo.com
Endonovo Therapeutics Inc (ENDV)
October 20, 2020 |  nasdaq.com
Endonovo Therapeutics’ Offers FDA Cleared Solution to Opioid Epidemic Which Has Significantly Increased During the COVID Pandemic.
October 8, 2020 |  markets.businessinsider.com
Endonovo Therapeutics Announces Encore Live Webinar of Baylor College of Medicine Study For Patients Undergoing Cardiothoracic Surgery Showing Reduction of Pain and Opioid Use With Significant Reduction of Length of Stay Using SofPulse®
September 9, 2020 |  finance.yahoo.com
Endonovo Therapeutics, Inc. Announces Second Quarter Fiscal 2020 Financial Results
August 20, 2020 |  finance.yahoo.com
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note
August 12, 2020 |  bloomberg.com
Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
July 27, 2020 |  finance.yahoo.com
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
July 21, 2020 |  finance.yahoo.com
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System
July 4, 2020 |  www.bloomberg.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ENDV
Previous Symbol
CUSIP
N/A
CIK
1528172
Web
www.endonovo.com
Phone
(800) 489-4774
Employees
1
Year Founded
N/A

Sales & Book Value

Annual Sales
$80,000.00
Price / Sales
18.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
-0.80

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-6.44 million
Net Margins
-5,033.33%
Return on Equity
N/A
Return on Assets
-264.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
61,559,000
Market Cap
$1.47 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions

What stocks does MarketBeat like better than Endonovo Therapeutics?

Wall Street analysts have given Endonovo Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Endonovo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Endonovo Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Endonovo Therapeutics' stock was trading at $0.3150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENDV stock has decreased by 92.4% and is now trading at $0.0239.
View which stocks have been most impacted by COVID-19.

Who are Endonovo Therapeutics' key executives?

Endonovo Therapeutics' management team includes the following people:
  • Alan Brian Collier, Chairman, CEO, CFO & Secretary
  • Don Calabria, Vice President-Operations
  • David Clark, Vice President-Sales
  • Steven Ford, Vice President-Marketing
  • Steven Barnes, Investor Relations Contact

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM).

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.02.

How much money does Endonovo Therapeutics make?

Endonovo Therapeutics has a market capitalization of $1.47 million and generates $80,000.00 in revenue each year.

How many employees does Endonovo Therapeutics have?

Endonovo Therapeutics employs 1 workers across the globe.

What is Endonovo Therapeutics' official website?

The official website for Endonovo Therapeutics is www.endonovo.com.

Where are Endonovo Therapeutics' headquarters?

Endonovo Therapeutics is headquartered at 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at (800) 489-4774 or via email at [email protected].


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.